Moderna COVID vaccine sales plunge by two-thirds in 2023, but meet company's $6B forecast

By CNBC
| January 08, 2024

The revenue from the shots met Moderna's forecast for the year, even as sales plummeted from the more than $18 billion the company booked in 2022.

Full story

#1

Recent research on Paxlovid shows there is "solid data on its effectiveness," a co-author of the study told HealthLeaders. ...

A new personal protective equipment manufacturing company is set to open in Cincinnati next year. ...